Who / What
Venetoclax is a medication sold under the brand names **Venclexta** and **Venclyxto**. It is used to treat adults with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and acute myeloid leukemia (AML). By attaching to the protein **Bcl‑2**, it helps induce cancer cell death.
Background & History
The development history of Venetoclax is not detailed in the provided data. The medication has been introduced under its brand names in the context of treating serious blood cancers. Key milestones such as approval dates or regulatory history are not supplied. The source focuses on clinical use rather than its origin.
Why Notable
Venetoclax is noteworthy for its targeted action against the Bcl‑2 protein, a critical factor in cancer cell survival. Its approval for CLL, SLL, and AML marks it as a significant therapeutic advancement in hematologic oncology. The drug’s side‑effect profile—including neutropenia, diarrhea, nausea, anemia, infections, and fatigue—highlights both its potency and the need for careful monitoring.
In the News
No current news or recent developments regarding Venetoclax are included in the supplied source. The information remains static and based on the established indications and safety profile.
